N6022

Research use only, not for human use.

A potent and reversible S-Nitrosoglutathione reductase (GSNOR) inhibitor with IC50 of 20 nM.

A potent and reversible S-Nitrosoglutathione reductase (GSNOR) inhibitor with IC50 of 20 nM; reduces bronchoconstriction and pulmonary inflammation in a mouse model of asthma and demonstrates an acceptable safety profile. Asthma Phase 2 Clinical(In Vitro):N6022 shows concentration-dependent binding to rat plasma proteins. N6022 has more effect on ATP at lower drug concentrations (20 μM) than on GSH. N6022 binds in the GSNO substrate binding pocket like a competitive inhibitor with an IC50 of 8 nM and a Ki of 2.5 nM. N6022 is uncompetitive with cofactors NAD+ and NADH.(In Vivo):N6022 (50 mg/kg)-treated rats show a slight increase in the incidence of granulomas. In serum, N6022 remains in solution up to 5 mg/mL.

——

——

N 6022 | N-6022

Metabolic Enzyme/Protease

GSNOR

S-nitrosoglutathionereductase(GSNOR)

Inflammation/Immunology

Asthma

1208315-24-5

414.4565

C24H22N4O3

>98% (HPLC)

DMSO: ≥ 46 mg/mL

O=C(O)CCC1=CC=C(C2=CC=C(N3C=CN=C3)C=C2)N1C4=CC=C(C(N)=O)C=C4C

1H-Pyrrole-2-propanoic acid, 1-[4-(aminocarbonyl)-2-methylphenyl]-5-[4-(1H-imidazol-1-yl)phenyl]-

(-20℃)

With Ice Pack

≥ 2 years